Key result
Following CTO PCI, antianginal medications are de-escalated in ~39% of patients at 6 months.
Why the study?
Patient characteristics associated with antianginal medication titration and variation in postprocedure antianginal medication management across hospitals after chronic total occlusion PCI had not been reported.
Observational (n=901)
Yes
Following CTO PCI, antianginal medications are most commonly left unchanged or de-escalated, with escalation associated with ongoing angina and periprocedural complications.
Answers are grounded in this paper and cite their sources.
Antianginal de-escalation or no change predominates after CTO PCI; leaves open optimal post-procedural strategies in observational data.
Background Prior research has shown that providers may infrequently adjust antianginal medications (AAMs) following chronic total occlusion (CTO) percutaneous coronary intervention (PCI). Patient characteristics associated with AAM titration and the variation in postprocedure AAM management after CTO PCI across hospitals have not been reported. We sought to determine the frequency and potential correlates of AAM escalation and de-escalation after CTO PCI. Methods and Results Using the 12-center OPEN CTO registry (Outcomes, Patient Health Status, and Efficiency iN Chronic Total Occlusion Hybrid Procedures), we assessed AAM use at baseline and 6 months after CTO PCI. Escalation was defined as any addition of a new class of AAM or dose increase, whereas de-escalation was defined as a reduction in the number of AAMs or dose reduction. Angina was assessed 6 months after the index CTO PCI attempt using the Seattle Angina Questionnaire Angina Frequency domain. Potential correlates of AAM escalation (vs no change) or de-escalation (vs no change) were evaluated using multivariable modified Poisson regression models. Adjusted variation across sites was evaluated using median rate ratios. AAMs were escalated in 158 (17.5%), de-escalated in 351 (39.0%), and were unchanged at 6-month follow-up in 392 (43.5%). Patient characteristics associated with escalation included lung disease, ongoing angina, and periprocedural major adverse cardiac and cerebral events (periprocedural myocardial infarction, stroke, death, emergent cardiac surgery, or clinically significant perforation), whereas de-escalation was more frequent among patients taking more AAMs, those treated with complete revascularization, and after treatment of non-CTO lesions at the time of the index procedure. There was minimal variation in either escalation (median rate ratio, 1.11; P=0.36) or de-escalation (median rate ratio, 1.10; P=0.20) compared to no change of AAMs across sites. Conclusions Escalation or de-escalation of AAMs was less common than continuation following CTO PCI, with little variation across sites. Further research is needed to identify patients who may benefit from AAM titration after CTO PCI and develop strategies to adjust these medications in follow-up. Clinical Trial Registration URL: https://www.clinicaltrials.gov . Unique identifier: NCT02026466.
No takes yet. Share an insight, caveat, or question.
Hirai et al. (2019) conducted an observational in Chronic total occlusion (CTO) (n=901). Antianginal medication escalation or de-escalation vs. No change in antianginal medications was evaluated on Frequency of antianginal medication escalation and de-escalation. Following chronic total occlusion PCI, antianginal medications were escalated in 17.5%, de-escalated in 39.0%, and unchanged in 43.5% of patients at 6 months, with minimal variation across sites.
Synapse has enriched 10 related papers. Consider them for comparative context: